ClinicalTrials.gg
Not yet recruitingNCT06361680Updated Apr 12, 2024

Effect of Coenzyme Q10 on Diabetic Children

An Early Phase 1 interventional study of Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets in Type 1 Diabetes Mellitus, sponsored by Assiut University. Not yet recruiting. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by Assiut University · Early Phase 1, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Diabetes Mellitus, Type 1 by Assiut University — 7 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Assiut University.

Started
2024
with 1 other
Phase 1
Only one
of the 11
Registered
6th of 11
by date

Among the 11 studies in Diabetes Mellitus, Type 1 by Assiut University, this one is one of 2 that started in 2024, is the only one in phase 1, and was the 6th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

7 of the 11 studies in Diabetes Mellitus, Type 1 by Assiut University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Diabetes Mellitus, Type 1 by Assiut University, or all of them as a file.
02

Study summary

Determine the effect of Coenzyme Q10 on random blood sugar and glycosylated haemoglobin

Read the detailed description

Type 1 diabetes mellitus is an autoimmune disease that leads to destruction of insulin producing pancreatic Beta cells.

Individuals with type 1 diabetes requires life long insulin replacement with multiple daily insulin injection. daily,insulin pump therapy or the use of an automated insulin delivery system.

without insulin ,diabetic ketoacidosis develops and is life threatening.

In addition to insulin Therapy ,glucose monitoring with a continuous glucose monitor and a blood glucose monitor if continuous glucose monitor is unavailable is recommended .

Coenzyme Q10 supplementation has beneficial effects on glycemic control especially in diabetes , and 100-200 mg per day of Co Q10 could achieve the greatest benefit which could provide a basis for the dietary guidelines of Co Q10 in patients with glycemic disorders .

Co Q10 with a known antiinflammatory and antioxidant has beneficial effects on endothelial function and therefore minimize the microvascular and macrovascular complication in patients with type 1 diabetes mellitus.

Administration of Co Q10 for 3 months in type 1 diabetes mellitus in pediatric patients was will tolerated but had no favorable effect on endothelial dysfunction or metabolic parameters .

Co Q10 in addition to improving the metabolic hyperglycemia , it improve Hb A1c and the lipid profile.

patients with type 1 diabetes , especially poorly controlled had elevation of plasma vitamin E and coenzyme Q10 levels and decreased platelet redox status of coenzyme Q10 which may be an indicator of increased oxidative stress ,so Co Q10 has an antioxidant effects.

Researches on this topic are limited on pediatrics and investigators search for it and will see the result.(clinical trial)

Co Q10 is present in the forms of soft gel capsules ,oral spray , hard gel capsules and tablets .

Co Q10 approved from age of 2 years old to 18 years old .

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients diagnosed as type 1 diabetes mellitus from age of 2 years old to 18 years old with diabetes mellitus of duration at least 1 year.

Exclusion criteria

Exclusion Criteria:

    • patients diagnosed as diabetes mellitus less than 2 years old .
  • patients with diabetes mellitus of duration less than 1 year.
  • patients diagnosed as type 1 diabetes mellitus with Thyroid or celiac diseases.
  • other types of hyperglycemia rather than Type 1 diabetes mellitus.
05

Study design

Phase
Early Phase 1
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Group A

    Will take Coenzyme Q10 soft gel capsules or tablets in a dose of 100-200mg of natural factors

    Drug: Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets

  • Experimental
    Group B

    Will not take Coenzyme Q10 soft gel capsules or tablets

    Drug: Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets

Interventions

  • DrugCoenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets

    Group A will take Soft gel capsules or tablets of Coenzyme Q10 in a dose of 100-200mg of natural factors or kirkman but group B will not take Coenzyme Q10 just observe them

    Also known as: Natural factors capsules or Kirkman tablets

06

What researchers measure

Primary outcomes

  1. Assess the effect of Coenzyme Q10 on glycated haemoglobin in type 1 diabetes mellitus

    This prospective randomized clinical trial will be conducted on 100 participants . Half of them will not receive treatment but group A will receive 100-200mg of Coenzyme Q10 . the level of glycated hemoglobin, fasting blood glucose will be assessed for both groups at baseline and after 3 months of treatment for ongoing use in diabetic children

    Time frame: One year

Secondary outcomes

  1. Control of random blood sugar and glycated haemoglobin in children with type 1 diabetes mellitus .

    By ensuring of regular intake of Coenzyme Q10 capsules or tablets then assessment of glycated hemoglobin

    Time frame: One year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Serag H, El Wakeel L, Adly A. Coenzyme Q10 administration has no effect on sICAM-1 and metabolic parameters of pediatrics with type 1 diabetes mellitus. Int J Vitam Nutr Res. 2021 Jun;91(3-4):315-324. doi: 10.1024/0300-9831/a000636. Epub 2020 Jan 16. PubMed 31942840 ↗
  • Sangouni AA, Taghdir M, Mirahmadi J, Sepandi M, Parastouei K. Effects of curcumin and/or coenzyme Q10 supplementation on metabolic control in subjects with metabolic syndrome: a randomized clinical trial. Nutr J. 2022 Oct 3;21(1):62. doi: 10.1186/s12937-022-00816-7. PubMed 36192751 ↗
  • Liang Y, Zhao D, Ji Q, Liu M, Dai S, Hou S, Liu Z, Mao Y, Tian Z, Yang Y. Effects of coenzyme Q10 supplementation on glycemic control: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. EClinicalMedicine. 2022 Aug 3;52:101602. doi: 10.1016/j.eclinm.2022.101602. eCollection 2022 Oct. PubMed 35958521 ↗
  • Stojanovic M, Radenkovic M. A meta-analysis of randomized and placebo-controlled clinical trials suggests that coenzyme Q10 at low dose improves glucose and HbA1c levels. Nutr Res. 2017 Feb;38:1-12. doi: 10.1016/j.nutres.2016.12.001. Epub 2016 Dec 8. PubMed 28381349 ↗
  • Salardi S, Zucchini S, Elleri D, Grossi G, Bargossi AM, Gualandi S, Santoni R, Cicognani A, Cacciari E. High glucose levels induce an increase in membrane antioxidants, in terms of vitamin E and coenzyme Q10, in children and adolescents with type 1 diabetes. Diabetes Care. 2004 Feb;27(2):630-1. doi: 10.2337/diacare.27.2.630. No abstract available. PubMed 14747266 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Oct 2025, 12 months later.

Of 56 non-industry phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 64. This study's planned 12 months is below that.

Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Apr 12, 2024
StartEst.
Oct 30, 2024
Primary completionEst.
Oct 30, 2025
CompletionEst.
Nov 30, 2025
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06361680
Lead sponsor
Assiut University
Responsible party
Christina Saad Abdel Malak Abdel Nour (Principal Investigator, Assiut University) — Principal investigator
First posted
Apr 12, 2024
Start date
Oct 30, 2024 (estimated)
Primary completion
Oct 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Apr 12, 2024

Study contacts

Faisal Alkhateeb Ahmad Abdullah, Professor
Contact
faisalalkhateeb@aun.edu.eg
01003858676
Christina Saad Abdel Malak Abdel Nour
Contact
tinasaad071@gmail.com
01270624513
Christina Saad Abdel Malak Abdel Nour
principal investigator · Study producer

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion